January 2018 in “Springer eBooks” Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
December 2017 in “Springer eBooks” Transplant patients often get skin problems, with treatments varying by condition.
September 2017 in “Pediatric Dermatology” The document concludes that an experimental drug may help wound healing in Epidermolysis Bullosa, links Hydroa vacciniforme to EBV, discusses diagnosing hair loss disorders, finds many children with eczema have allergies, reviews the safety of a skin medication in children, notes side effects of a Duchenne's treatment, and identifies a marker for pediatric mastocytosis.
August 2012 in “Pharmaceutical Medicine” The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.
Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.
306 citations
,
August 2011 in “Journal of cachexia, sarcopenia and muscle” Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
7 citations
,
August 2025 in “European Journal of Endocrinology” Long-term use of calcineurin inhibitors in transplant patients can cause hormone issues that can be managed with proper care.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
192 citations
,
January 2015 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause serious skin problems that need careful management.
3 citations
,
February 2010 in “Clinical kidney journal” Combining ciclosporin and simvastatin can cause severe kidney damage.
17 citations
,
December 1997 in “Transplantation” Tacrolimus can cause hair loss in kidney transplant patients.
The document corrects a mistake by stating that pimecrolimus, not tacrolimus, is the drug that concentrates in the skin.
June 2026 in “Frontiers in Medicine” Spironolactone has the most side effects, including serious risks, while eplerenone and finerenone mainly affect the heart, kidneys, and metabolism.
234 citations
,
September 2004 in “Clinical cancer research” BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
2 citations
,
October 2025 in “Frontiers in Medicine” Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
November 2020 in “Universal Journal of Pharmaceutical Research” Tacrolimus is a better option than cyclosporine due to fewer side effects.
5 citations
,
May 2017 in “Journal of dermatological science” The combined treatment effectively managed severe skin issues in Olmsted syndrome.
11 citations
,
August 2021 in “Stem Cell Research & Therapy” Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.
January 2026 in “Vestnik dermatologii i venerologii” Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.
33 citations
,
May 2001 in “Annals of pharmacotherapy/The annals of pharmacotherapy” Topical tacrolimus is safe and effective for skin conditions, but oral tacrolimus has serious side effects.
April 2017 in “Journal of Investigative Dermatology” Sirolimus and propranolol may reduce abnormal cell growth and improve lymphatic malformations in children.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
1 citations
,
March 2023 in “Journal of the American College of Cardiology” 8 citations
,
August 2016 in “Journal of the European Academy of Dermatology and Venereology” Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
6 citations
,
June 2009 in “Clinical and Experimental Dermatology” Topical tacrolimus reduces certain growth factors in hair follicles.
March 2017 in “Fundamental & Clinical Pharmacology” The model and estimator can predict drug exposure in kidney transplant patients well.
February 2025 in “Canadian Journal of Health Technologies” Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
4 citations
,
June 2020 in “BMC Ophthalmology” Minoxidil can cause a rare eye condition, but it was successfully treated with oral Eplerenone in one case.